Trials
99 active
134 in total · 121 in the EU
Targets
—
None known yet
What this is
- How it works
- Thalidomide Analog FDA class
- Main trialPhase 3
- “The purpose of this study is to compare the efficacy and safety of mezigdomide (CC-92480), bortezomib and dexamethasone (MeziVd) versus pomalidomide, bortezomib and dexamethasone (PVd) in participants with relapsed or refractory multiple myeloma (RRMM) who received between 1 to 3 prior lines of therapy and who have had prior lenalidomide exposure.”In the company’s words, NCT05519085 on ClinicalTrials.gov
- Other names
- POM · Dexamethasone · Pomalyst · CC-4047 · immunomodulatory agent · Imnovid
Other drugs for Relapsed or Refractory Multiple Myeloma
- DostarlimabGSK · Phase 3
- NiraparibGSK · Phase 3
- MezigdomideCelgene · Phase 3
- PlonmarlimabTJ Biopharma Co., Ltd. · Phase 3
- GumarontinibCSPC · Phase 2/3
- SelinexorKaryopharm Therapeutics Inc · Phase 2/3
Coming up2
- 10 Jan 2027Phase 3 trial completes · ClinicalTrials.gov
- 30 Dec 2027Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials134
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 10 Jan 2027 | A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) | |
| Phase 3Recruiting | 30 Dec 2027 | A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2) | |
| Phase 3Completed | 11 Dec 2019 | Evaluation of Safety of Pomalidomide in Combination With Dexamethasone (Low Dose) in Patients With Refractory or Relapsed and Refractory Multiple Myeloma | |
| Phase 3Completed | 9 Mar 2022 | An Investigational Immuno-therapy Study of Nivolumab, Pomalidomide and Dexamethasone Combinations in Patients With Multiple Myeloma | |
| Phase 3Completed | 9 May 2022 | Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma | |
| Phase 3Withdrawn | 16 Nov 2025 | A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) | |
| Phase 3Completed | 13 Apr 2026 | Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) | |
| Phase 2Terminated | 3 Nov 2016 | Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Patients With Systemic Sclerosis With Interstitial Lung Disease | |
| Phase 2Completed | 17 Jan 2018 | An Investigational Immuno-therapy Trial of Pomalidomide and Low-dose Dexamethasone With or Without Elotuzumab to Treat Refractory and Relapsed and Refractory Multiple Myeloma (ELOQUENT-3) | |
| Phase 2Completed | 29 Jul 2019 | A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone and Elotuzumab in Combination With Nivolumab in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide. | |
| Phase 2Terminated | 3 Jan 2022 | A Study to Determine the Safety and Efficacy for the Combination of Durvalumab and Daratumumab in Relapsed and Refractory Multiple Myeloma | |
| Phase 2Completed | 14 Sep 2023 | A Study of Pomalidomide Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors | |
| Phase 2Completed | 30 Apr 2025 | Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following Lenalidomide-based Therapy in the First or Second Line Setting | |
| Phase 2Completed | 23 Feb 2026 | Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab | |
| Phase 1/2Completed | 25 Sep 2020 | An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma | |
| Phase 1Completed | 7 Aug 2018 | Study of Pomalidomide to Evaluate the Pharmacokinetics and Safety for Patients With Multiple Myeloma and Impaired Renal Function (POM Renal) | |
| Phase 1Completed | 23 Nov 2018 | A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma | |
| Phase 1Terminated | 3 Jun 2024 | Study of ACY-241 Alone and in Combination With Pomalidomide and Dexamethasone in Multiple Myeloma | |
| Phase 2Authorised | not given | Randomized phase II trial for patients with newly diagnosed low-risk multiple myeloma to evaluate the benefit of 6 cycles of isatuximab with lenalidomide/bortezomib/dexamethasone (I-VRD) followed by maintenance therapy with lenalidomide and isatuximab randomized in comparison with therapy consisting of 3 cycles of I-VRD followed by one cycle of high-dose therapy and maintenance therapy with lenalidomide and isatuximab | |
| Phase 2/3Authorised | not given | ALLTogether1 - A Treatment Study Protocol of the ALLTogether Consortium for Children and Young Adults (0-45 Years of Age) with Newly Diagnosed Acute Lymphoblastic Leukaemia (ALL) | |
| Phase 2Authorised | not given | Pembro-CORE pilot - Phase II trial of Pembrolizumab in COmbination with salvage chemotherapy for first-RElapsed or refractory classical Hodgkin lymphoma | |
| Phase 3Authorised | not given | The DEXA-PSYCH Study: Dexamethasone Repurposing for Moderate to Severe Depression - A Double-Blind, Randomized, Parallel-Group, Placebo-Controlled Trial | |
| Phase 4Authorised | not given | Trans-arterial treatment of patients with intra-hepatic cholangiocarcinoma not amenable to resection (TOMCAT) | |
| Phase 3Authorised | not given | COBEX-PED Corticosteroids before extubation in pediatric intensive care unit: a prospective randomized double-blind multicenter study | |
| Phase 3/4Ended | not given | A phase IV, open, non-randomised, low-intervention clinical trial to evaluate the subjective user experience of Zeqmelit™ 6 mg mouth dissolving film for treatment of acute allergic reaction | |
| Phase 2Authorised | not given | A Phase 2, Multi-cohort Study Applying Innovative MRD Techniques for Transplant Eligible Participants with Previously Untreated Multiple Myeloma - TAURUS | |
| Phase 3Authorised | not given | Efficacy of intravenous dexamethasone in prolonging the duration of spinal anesthesia with chloroprocaine in knee arthroscopy. | |
| Phase 3Authorised | not given | A Randomized Intervention, Multi-Center Study to Determine the Role of Dexamethasone eye drops against proliferative retinopathy of prematurity | |
| Phase 3Authorised | not given | B-NHL 2013 - Treatment protocol of the NHL-BFM and the NOPHO study groups for mature aggressive B-cell lymphoma and leukemia in children and adolescents | |
| Phase 2Authorised | not given | Hyper-CVAD/MA for high-risk aggressive B-cell lymphomas: a single-centre academic phase II trial (HYPERION) | |
| Phase 2Ended | not given | Immunomodulatory effects of dexamethasone, tocilizumab and anakinra during experimental human endotoxemia: the DEDICATE-LPS study | |
| Phase 2Authorised | not given | Pulse corticosteroids or/and Immunoglobulins to treat fulminant Myocarditis: a double-blind randomized controlled adaptive trial (The CORIUM study) | |
| Phase 2Authorised | not given | Daratumumab, pomalidomide and dexamethasone for del(17p) positive relapsed and relapsed/refractory multiple myeloma patients [DEDALO] | |
| Phase 3Ended | not given | A Phase 3 Double-masked, Randomized, Multicenter Study of the Efficacy and Safety of OCS-01 Eye Drops in Subjects With Diabetic Macular Edema | |
| Phase 3Authorised | not given | RANDOMISED EVALUATION OF COVID-19 THERAPY (RECOVERY) | |
| Phase 3/4Authorised | not given | Evaluation of the omission of dexamethasone in premedication regimens during paclitaxel treatment | |
| Phase 3Authorised | not given | A Phase 3 Randomized Study Comparing Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Ciltacabtagene Autoleucel versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Autologous Stem Cell Transplant (ASCT) in Participants with Newly Diagnosed Multiple Myeloma who are Transplant Eligible | |
| Phase 3Authorised | not given | Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia | |
| Phase 2Authorised | not given | Improving public cancer care by implementing precision medicine in Norway A multi-cohort phase 2 treatment clinical study investigating efficacy of approved drugs outside indication in patients with advanced cancer. IMPRESS-Norway | |
| Phase 3Authorised | not given | LBL 2018 - International cooperative treatment protocol for children and adolescents with lymphoblastic lymphoma | |
| Phase 3Authorised | not given | Dexamethasone for treating severe hospital-acquired pneumonia in critically ill patients with a proinflammatory phenotype, an international phase III, double-blind, placebo-controlled, randomized trial - the HAP-DEX study | |
| Phase 2Authorised | not given | Minimal Residual Disease-based Strategy with T-Cell Redirector After Treatment with Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma: A Phase 2 (IFM 2022-01). | |
| Phase 2Authorised | not given | EORTC-1537-LYMG: Very early FDG-PET-response adapted targeted therapy for advanced Hodgkin lymphoma: a single-arm phase II study | |
| Phase 3Authorised | not given | HOVON 174 MM: FeAsiBility of a treatment free interval in newly diagnosed mUltiple myeLOma patients treated with DaratumUmab-Lenalidomide-DexamethaSone – the FABULOUS study | |
| Phase 2Authorised | not given | ICON study: A phase 2 study of CC220 (iberdomide) combined with low-dose cyclophosphamide and dexamethasone in relapsed/refractory multiple myeloma (IberCd) | |
| Phase 3Authorised | not given | Newly Diagnosed Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL). Sequential Treatment with Ponatinib and the Bispecific Monoclonal Antibody Blinatumomab vs Chemotherapy and Imatinib. ALL2820 | |
| Phase 3Authorised | not given | AIEOP-BFM ALL 2017 - International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia | |
| Phase 4Authorised | not given | A randomized clinical two-arm trial comparing inflammation and cystoid macular edema for the medication regimens postoperative topical NSAIDs and steroids to only postoperative topical steroids in patients undergoing corneal endothelial transplantations (DMEC). | |
| Phase 2Authorised | not given | A Phase 2, single arm, open label, multicenter study to assess minimal residual disease after isatuximab in combination with bortezomib and lenalidomide with minimal dexamethasone in patients with newly diagnosed multiple myeloma ineligible for autologous transplant. | |
| Phase 2/3Authorised | not given | RElapse from Mrd Negativity As iNdication for Treatment | |
| Phase 2Authorised | not given | Phase II Open-Label, Single Arm, Multicenter Study of Ciltacabtagene Autoleucel in High-Risk Smoldering Multiple Myeloma (GEM-CAR-HiRiSMM) | |
| Phase 2/3Authorised | not given | Glo-BNHL: A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma | |
| Phase 3Authorised | not given | Free regimen of Dexamethasone as initial therapy for advanced relapsed/refractory multiple myeloma: an open-label randomized, non-inferiority, controlled trial (FREEDOM) | |
| Phase 2Authorised | not given | HOVON 147 MM: Carfilzomib, Lenalidomide and Dexamethasone versus Lenalidomide and Dexamethasone in High- Risk Smoldering Multiple Myeloma: A Randomized Phase 2 Study. | |
| Phase 4Not authorised | not given | Efficacy of peri-operative dexamethasone administration in single bundle anterior cruciate ligament reconstruction: a prospective randomized double-blinded placebo-controlled trial | |
| Phase 4Authorised | not given | Erector Spinae Plane Block for acute low back pain: a prospective double-blind randomized multicenter study. ESP-BACK | |
| Phase 2Authorised | not given | An Open Label, Phase 2 Study to Evaluate Activity and Safety of Daratumumab in combination with Bortezomib and Dexamethasone in patients with Relapsed or Refractory Plasmablastic lymphoma (DALYA trial) | |
| Phase 2Ended | not given | Randomized, multicentre phase II trial of the sequencing of Radium-223 and Docetaxel plus prednisone in symptomatic bone-only metastatic castration-resistant prostate cancer (mCRPC) | |
| Phase 2Authorised | not given | Clinical Trial on PREnatal Dexamethasone In Congenital adrenal hyperplasia Therapy - PREDICT - | |
| Phase 2Ended | not given | KRd consolidation in myeloma patients with a positive PET-CT after standard first line treatment. A phase II study | |
| Phase 2Authorised | not given | A multicenter, open label, randomized phase II study comparing daratumumab combined with bortezomib-cyclophosphamide-dexamethasone (Dara-VCd) versus the association of bortezomib-thalidomide-dexamethasone (VTd) as pre transplant induction and post transplant consolidation, both followed by a maintenance phase with ixazomib alone or in combination with daratumumab, in newly diagnosed multiple myeloma (MM) young patients eligible for autologous stem cell transplantation | |
| Phase 3Authorised | not given | APICALE - Cervical facet injection of corticosteroids for the management of cervicobrachialgia : protocol for a randomized pilot study | |
| Phase 3Authorised | not given | Anesthetic block of the erector muscles of the lumbar spine to relieve acute lumbar pain: pilot study | |
| Phase 3Authorised | not given | A multi-center phase III randomized study comparing continuous versus fixed duration therapy with Daratumumab, Lenalidomide, and Dexamethasone for relapsed multiple myeloma (CONFIRM) | |
| Phase 4Ended | not given | A RANDOMIZED, MULTICENTER, OPEN LABEL STUDY COMPARING TWO STANDARD TREATMENTS, BORTEZOMIB-MELPHALAN-PREDNISONE (VMP) WITH OR WITHOUT DARATUMUMAB (Dara-VMP) VS LENALIDOMIDE-DEXAMETHASONE (Rd) WITH OR WITHOUT DARATUMUMAB (Dara-Rd) IN AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) INELIGIBLE COMMUNITY POPULATION AFFECTED BY MULTIPLE MYELOMA (MM) – Real MM | |
| Phase 4Authorised | not given | Cataract surgery and Inflammation – the role for preoperative NSAIDs (pre-CIN) | |
| Phase 2Authorised | not given | Selinexor with alternating bortezomib or lenalidomide plus dexamethasone in transplant ineligible newly diagnosed multiple myeloma patients (SABLe): An Investigator Sponsored Trial | |
| Phase 3Ended | not given | FINISHER – Fight INflammation to Improve outcome after aneurysmal Subarachnoid HEmorRhage | |
| Phase 2Ended | not given | Extended Criteria Treatment for Liver Metastases With Heavy Tumour Burden | |
| Phase 2Authorised | not given | Venetoclax and Dexamethasone in translocation (11;14) positive relapsed and refractory multiple myeloma (VICTORIA) | |
| Phase 2Authorised | not given | Isa-RVD Study: Phase II, Multi-centre, Single-Arm, Open-Label Study to evaluate the efficacy and safety of the combination regimen Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma | |
| Phase 1/2Authorised | not given | Pomalidomide as an immune-enhancing agent for the control of HIV (PEACH): An investigator-initiated phase I/IIb clinical trial in people living with HIV on ART and during analytical treatment interruption. | |
| Phase 3Authorised | not given | Randomised, double-blind, multicentre, phase III clinical trial to evaluate the efficacy and safety of dexamethasone compared to placebo in patients with severe influenza (FLUDEX) | |
| Phase 2Authorised | not given | Pilot phase II study of Selinexor in combination with Ifosfamide, Etoposide and Dexamethasone (SIDE) in patients with relapsed or refractory Peripheral T-cell Lymphomas | |
| Phase 3Authorised | not given | CARFILZOMIB - LENALIDOMIDE - DEXAMETHASONE (KRd) versus LENALIDOMIDE - DEXAMETHASONE (Rd) IN NEWLY DIAGNOSED MYELOMA PATIENTS NOT ELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANTATION: A RANDOMIZED PHASE III TRIAL (EMN20) | |
| Phase 2Authorised | not given | Isatuximab and Autologous Hematopoietic Stem Cell Transplantation for Relapsed Multiple Myeloma Patients (Isabel study) | |
| Phase 3Authorised | not given | Phase III study of Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone (Isa-KRd) versus Carfilzomib-Lenalidomide-Dexamethasone (KRd) in newly diagnosed multiple myeloma patients eligible for autologous stem cell transplantation (IsKia TRIAL) | |
| Phase 2Ended | not given | A phase 2, open label, multicenter, single-stage study to evaluate the efficacy of Isatuximab plus Pomalidomide and Dexamethasone (IPd), in patients with AL amyloidosis not in VGPR or better after any previous therapy | |
| Phase 2Authorised | not given | An open label, multicenter, Phase 2, pilot study, evaluating early treatment with bispecific T-cell redirectors (teclistamab and talquetamab) in the frontline therapy of newly diagnosed high-risk multiple myeloma | |
| Phase 3Ended | not given | A Phase 3 Study Comparing Lenalidomide and Daratumumab Subcutaneous Injection (R-Dara SC) vs Lenalidomide and Dexamethasone (Rd) in Frail Subjects with Previously Untreated Multiple Myeloma who are Ineligible for High Dose Therapy. | |
| Phase 2Ended | not given | LOADEX: PILOT AND PHASE 2 STUDY OF THE EFFICACY OF A TREATMENT PROTOCOL WITH DEXAMETHASONE IMPLANT LOADING DOSE IN PATIENTS WITH DIABETIC MACULAR EDEMA | |
| Phase 2Not authorised | not given | MELFLUFEN FOR ELDERLY MYELOMA PATIENTS IN SECOND OR SUBSEQUENT RELAPSE (MELISSA) | |
| Phase 2Authorised | not given | Daratumumab in combination with Carfilzomib, Pomalidomide and Dexamethasone (DCPD) in patients with multiple myeloma induced acute renal failure - "Time is Kidney in the Treatment of myeloma Cast nephropathy" The TIKTAC phase II trial (Pilot-study) | |
| Phase 2Authorised | not given | Daratumumab combined with Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting with Extramedullary Disease | |
| Phase 1/2Authorised | not given | Phase 1/2 trial evaluating isatuximab in combination with belantamab mafodotin and dexamethasone in relapsed or refractory multiple myeloma (RRMM) | |
| Phase 1/2Authorised | not given | Phase 1/2 trial evaluating isatuximab in combination with SAR445761 (belumosudil) and dexamethasone in relapsed or refractory multiple myeloma (RRMM) | |
| Phase 1/2Authorised | not given | Phase 1/2 trial evaluating isatuximab in combination with evorpacept and dexamethasone in relapsed or refractory multiple myeloma (RRMM) | |
| Phase 2Authorised | not given | PCL-2 - PRIMARY PLASMA CELL LEUKEMIA: A PROSPECTIVE PHASE II STUDY INCORPORATING DARATUMUMAB TO CHEMOTHERAPY AND STEM CELL TRANSPLANTATION (PCL-2 STUDY) | |
| Phase 4Authorised | not given | Innovative Steroid Treatment to Reduce Asthma Development in Children After First-time Rhinovirus Induced Wheezing - The INSTAR study | |
| Phase 3Authorised | not given | International phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones | |
| Phase 1/2Authorised | not given | A PHASE 1/2, DOSE AND SCHEDULE EVALUATION STUDY TO INVESTIGATE THE SAFETY AND CLINICAL ACTIVITY OF BELANTAMAB MAFODOTIN ADMINISTERED IN COMBINATION WITH DARATUMUMAB, LENALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TRANSPLANT INELIGIBLE | |
| Phase 3Authorised | not given | Elotuzumab (E) in Combination with Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) versus KRd prior to and following Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma and Subsequent Maintenance with Elotuzumab and Lenalidomide versus Single-Agent Lenalidomide - A phase III study by DSMM (Deutsche Studiengruppe Multiples Myelom) | |
| Phase 3Ended | not given | Dexamethasone in Herpes Simplex Virus Encephalitis Open label Randomized Controlled Trial with an Observer-blinded evaluation at 6 months | |
| Phase 2Authorised | not given | A PHASE 1/2, DOSE AND SCHEDULE EVALUATION STUDY TO INVESTIGATE THE SAFETY AND CLINICAL ACTIVITY OF BELANTAMAB MAFODOTIN ADMINISTERED IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TRANSPLANT INELIGIBLE | |
| Phase 2Authorised | not given | A Phase 2 Study of Isatuximab in combination with Pomalidomide and Dexamethasone in MM Patients who received one prior line of therapy containing Lenalidomide and a Proteasome Inhibitor | |
| Phase 2Ended | not given | A Phase 2 Study of Isatuximab in combination with Bortezomib, Cyclophosphamide and Dexamethasone followed by isatuximab and lenalidomide maintenance in Newly Diagnosed Patients with Multiple Myeloma and severe Renal Impairment | |
| Phase 2Ended | not given | An open label, multicenter, phase II study of belantamab mafodotin in combination with VRd for the treatment of newly diagnosed transplant eligible multiple myeloma patients | |
| Phase 1/2Authorised | not given | A PHASE 1/2, DOSE AND SCHEDULE EVALUATION STUDY TO INVESTIGATE THE SAFETY AND CLINICAL ACTIVITY OF BELANTAMAB MAFODOTIN ADMINISTERED IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE WITH OR WITHOUT DARATUMUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA PREVIOUSLY TREATED WITH ONE TO THREE LINES OF THERAPY WHO ARE LENALIDOMIDE REFRACTORY | |
| Phase 2Authorised | not given | Phase 2 study of belantamab mafodotin in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma | |
| Phase 2Authorised | not given | A multi-center open-label phase 2 study of Ixazomib, Iberdomide and dexamethasone in elderly patients with multiple myeloma at first relapse | |
| Phase 3Authorised | not given | Intravenous Immunoglobulin plus oral prednisone or high-dose dexamethasone, for adults with immune thrombocytopenia (ITP) with moderate and severe bleeding: a randomized, multicentre trial (IVIORDEX) | |
| Phase 2Ended | not given | ISKPD-IFM2018-03-Multicenter Open label Phase 2 study of Isatuximab plus Pomalidomide and Dexamethasone with Carfilzomib in Relapsed or Refractory Multiple Myeloma | |
| Phase 2Authorised | not given | A phase II multicenter study of carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy, followed by high-dose therapy with melphalan and autologous peripheral blood stem cell transplantation, consolidation with KRd, and maintenance with lenalidomide and dexamethasone in patients ≤ 70 years old with smoldering multiple myeloma (SMM) with high risk of progression to symptomatic myeloma | |
| Phase 4Authorised | not given | ASSESSMENT OF THE EFFICACY IN REDUCING EDEMA, TRISMUS AND PAIN, OF DEXAMETHASONE ACCORDING TO DIFFERENT INTRAORAL AND EXTRAORAL PREOPERATIVE APPLICATION ROUTES, IN THE SURGERY OF RETAINED LOWER THIRD MOLARS. | |
| Phase 3Authorised | not given | Collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia. A randomized phase III study conducted in agreement with the AIEOP-BFM study group. | |
| Phase 3/4Authorised | not given | CRYSTAL : Comparison of topical hydrocortisone versus dexamethasone treatment for inflammatory secretions of the conjunctiva in patients with ocular prostheses | |
| Phase 4Ended | not given | Comparison of treatment with preservative-free dexamethasone 0.1% (Monofree Dexamethason) and diclofenac 0.1% (Dicloabak) eye drops versus preserved dexamethasone 0.1% (Maxidex) and diclofenac 0.1% (Voltaren Ophtha) eye drops after cataract surgery. | |
| Phase 3Authorised | not given | Effect of early dexamethasone on major complications and all-cause mortality in severe burns | |
| Phase 2Authorised | not given | A phase 1/2, dose and schedule evaluation study to investigate the safety and clinical activity of belantamab mafodotin administered in combination with lenalidomide and dexamethasone in patients with transplant ineligible newly diagnosed multiple myeloma | |
| Phase 3Ended | not given | HD21 for advanced stages - Treatment optimization trial in the first-line treatment of advanced stage Hodgkin lymphoma; comparison of 4-6 cycles of escalated BEACOPP with 4-6 cycles of BrECADD | |
| Phase 4Authorised | not given | EFFECT OF DEXAMETASONE ON LOWER LIMB EDEMA IN PATIENTS UNDERTAKEN FOR TOTAL HIP ARTHROPLASTY | |
| Phase 2Authorised | not given | An Investigator-Initiated, Phase II, Multicenter, Open-Label, Single-Arm, Prospective Clinical Trial to Evaluate the Efficacy and Safety of Alternating Bortezomib-Based Regimens in Combination with DaratUMumab followed by Maintenance with Daratumumab in the Frontline Setting of Primary Plasma CEll LEukemIA: A Trial of the Greek Myeloma Study Group. The “EUMELEIA” Study | |
| Phase 2Authorised | not given | A phase II efficacy and safety study of cell-free circulating tumor DNA-guided commencement of second-line treatment in patients with DLBCL/HGBCL relapse | |
| Phase 3Authorised | not given | A PHASE 3 RANDOMIZED, OPEN-LABEL TRIAL OF SELINEXOR, POMALIDOMIDE, AND DEXAMETHASONE (SPd) VERSUS ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EloPd) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) | |
| Phase 2/3Authorised | not given | Ruxolitinib for childhood ALL in Poland (Rux-cALL-Pol 2020 trial) - Single-arm interventional study with ruxolitinib and AIEOP-BFM 2017 Poland or AIEOP-BFM 2017 standard of care chemotherapy in children with acute lymphoblastic leukemia and confirmed activation of JAK/STAT pathway. | |
| Phase 3Authorised | not given | A Randomized, Open-label Phase 3 Study of Carfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA) | |
| Phase 4Authorised | not given | Efficacy of Higher vs. Lower Doses of Dexamethasone in Patients With Acute Hypoxemic Respiratory Failure (Including ARDS) Caused by Infections (Including COVID-19) | |
| Phase 3Authorised | not given | A Randomized, Open-Label, Controlled Phase 3 Study Comparing Daratumumab, Lenalidomide and Dexamethasone Induction followed by Linvoseltamab Versus continued Daratumumab, Lenalidomide, and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma Patients | |
| Phase 4Authorised | not given | Lantiolihaspuudutuksen vaikutus munuaisen poistoleikkauksen jälkeiseen kivun hoitoon ja toipumiseen | |
| Phase 3Authorised | not given | TAILORED-PROM: TAILORED therapeutic regime in patients with preterm Premature Rupture Of Membranes to prolong pregnancy, improve maternal and neonatal outcomes, and reduce antibiotic burden | |
| Phase 3Authorised | not given | CYPENZA - A prospective cohort trial on antiandrogens influences on the pharmacokinetics of corticosteroids. | |
| Phase 4Authorised | not given | Dexamethasone for the treatment of traumatic brain injured patients with brain contusions and pericontusional edema: Study protocol for a prospective, randomized and double blind trial | |
| Phase 1/2Authorised | not given | Pomalidomide in people with chronic hepatitis B virus (HBV) infection: Safety and immune-enhancing effects (The PIPPI Study) | |
| Phase 2Authorised | not given | A Phase 2, single arm Multicenter, Study testing Mezigdomide, Carfilzomib, and Dexamethasone (480Kd) in Participants with Relapsed or Refractory Multiple Myeloma (RRMM). (MEZI-KD) | |
| Phase 2Authorised | not given | BASTION – Phase II Trial of BrECADD in HIV-Positive Patients with Advanced-Stage Classic Hodgkin Lymphoma | |
| Phase 3Authorised | not given | Premedication with dexamethasone for preventing interstitial lung disease in patients with breast cancer treated with trastuzumab deruxtecan | |
| Phase 2Authorised | not given | A Phase II, Open-label, Multicenter Study Testing Teclistamab in Combination with Pomalidomide Administered in Alternative Fashion in Participants with RRMM, who Received 1 - 3 Prior Lines of Therapy, Including Lenalidomide and Anti-CD38 Therapy | |
| Phase 3Authorised | not given | AIEOP-BFM ALL 2025 - International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia | |
| Phase 3/4Authorised | not given | Comparison of low versus intermediate intravenous dexamethasone doses on rebound pain after ambulatory open foot surgery under popliteal sciatic nerve block: a double-blind clinical trial. | |
| Phase 3Authorised | not given | Effect of nepafenac/dexamethasone fixed dose combination vs. its individual components (nepafenac and dexamethasone monotherapies) on postoperative inflammation after cataract surgery: a randomized, multicentre, blinded-assessor, parallel-group clinical study – NE.DE.F. STUDY | |
| Phase 2Authorised | not given | PAROCAINE : Evaluation of the Clinical Tolerance of an Intra-Parotid Injection of Bupivacaine Combined with Dexamethasone After Parotidectomy for a Benign Tumor – Prospective Single-Center Cohort Study | |
| Phase 4Authorised | not given | The effect op corticosteroids on quality of life following total hip arthroplasty: HIPSTER study | |
| Phase 3Authorised | not given | ECSIP : Early Corticosteroids in Severe Influenza Pneumonia, a phase III randomized controlled trial | |
| Phase 3Authorised | not given | Finnish Dexamethasone Trial for Chronic Subdural Hematoma (FINDEX): A Multicenter, Double-Blind, Placebo-Controlled Randomized Controlled Trial |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026